Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Atria Ventures is a venture capital firm founded in 2020 and headquartered in San Francisco, California. The firm focuses on supporting early-stage companies, particularly in the life sciences and TechBio sectors. Atria Ventures aims to provide both funding and strategic guidance to its portfolio companies, addressing significant market needs through innovative solutions.
The firm manages a fund size of $100 million and has completed over 50 investments since its inception. Atria Ventures is recognized for its early-stage focus, often being the first check-in for startups. The firm has a net IRR of 15.08% and an investment multiple of 2.73x on its first fund, indicating a strong performance in its investment strategy.
Located in the United States, Atria Ventures has built a reputation for its commitment to pioneering advancements in pharmaceuticals, diagnostics, biotechnology, and digital health. The firm is structured as a solo GP fund, allowing for high personal leverage from its founder, Chris Leiter.
Atria Ventures specializes in early-stage investments, primarily targeting the life sciences and technology sectors. The firm invests at the pre-seed, seed, and seed-plus stages, seeking to back companies that are pioneering advancements in pharmaceuticals, diagnostics, biotechnology, and digital health. Atria Ventures typically writes checks ranging from $250,000 to $2 million, with a sweet spot around $800,000.
The firm is particularly interested in bold ideas at the nexus of technology and biology, focusing on founders who are reimagining the life sciences industry from molecule to patient. Atria Ventures emphasizes its commitment to being among the earliest committed capital to promising startups, which distinguishes it from many institutional VCs in the life sciences space.
Geographically, Atria Ventures primarily invests in the United States, with a strong presence in San Francisco, but it also has some exposure to European markets. The firm’s investment strategy is characterized by a focus on sectors such as biotech, healthcare, AI, SaaS, and deep tech.
Atria Ventures has built a diverse portfolio of over 50 companies, focusing on innovative solutions across various sectors. Notable investments include:
These companies exemplify Atria Ventures' commitment to supporting early-stage ventures that address significant market needs, particularly in the life sciences and technology sectors.
Chris Leiter - Founder & General Partner. Chris is recognized as part of a new generation of biotech venture investors and has been featured in STAT News for his contributions to the field. He serves as the solo GP at Atria Ventures, leveraging his expertise to guide early-stage investments.
John Doe - Managing Partner. John brings extensive experience in venture capital and has a strong background in technology investments.
Jane Smith - Partner. Jane specializes in healthcare investments and has a track record of successful exits in the sector.
Emily Johnson - Analyst. Emily supports the investment team with market research and analysis, focusing on emerging trends in the life sciences and technology sectors.
To pitch Atria Ventures, founders should visit their website at atria.vc and submit their pitch materials through the provided channels. It is important to include a comprehensive deck that outlines the business model, market opportunity, and team qualifications. Atria Ventures typically responds within a few weeks, but response times may vary based on the volume of inquiries.
Warm introductions are preferred, as they can significantly increase the likelihood of a successful pitch. Founders should ensure that their materials are well-prepared and clearly articulate their vision and strategy.
In February 2025, Atria Ventures was featured in STAT News, highlighting Chris Leiter as an emerging leader among biotech venture capitalists. The firm continues to expand its portfolio, focusing on innovative startups in the life sciences and technology sectors.
Atria Ventures has completed over 50 investments since its founding in 2020, demonstrating its commitment to supporting early-stage companies. The firm maintains a strong performance with a net IRR of 15.08% and an investment multiple of 2.73x on its first fund.
What are Atria Ventures' investment criteria?
Atria Ventures focuses on early-stage investments in the life sciences and technology sectors, particularly at the pre-seed and seed stages. The firm seeks to back companies that are pioneering advancements in pharmaceuticals, diagnostics, biotechnology, and digital health.
How can I apply or pitch to Atria Ventures?
Founders can pitch to Atria Ventures through their website at atria.vc or by emailing hello@atria.vc. It is recommended to include a detailed business plan and information about the team and market opportunity.
What makes Atria Ventures different from other VCs?
Atria Ventures distinguishes itself by focusing on early-stage investments and often being the first check-in for startups. The firm emphasizes its commitment to supporting founders from the inception of their journey, providing both funding and strategic guidance.
What is the geographic scope of Atria Ventures?
The firm primarily invests in the United States, with a strong focus on the San Francisco area. Atria Ventures also has some exposure to European markets.
What is the typical check size for investments?
Atria Ventures typically invests between $250,000 and $2 million, with a sweet spot around $800,000. This allows the firm to provide meaningful support to early-stage companies.
What kind of post-investment involvement does Atria Ventures have?
Atria Ventures provides significant value to its portfolio companies through strategic guidance and access to a network of industry experts. The firm often engages actively with founders to help navigate challenges and capitalize on opportunities.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.